Cytosar Side Effects
Generic Name: cytarabine
Note: This page contains information about the side effects of cytarabine. Some of the dosage forms included on this document may not apply to the brand name Cytosar.
Not all side effects for Cytosar may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.
For the Consumer
Applies to cytarabine: parenteral conventional cytarabine injection, parenteral conventional cytarabine powder for injection, parenteral liposomal cytarabine injection
Side effects include:
IV, sub-Q, or IM administration of conventional cytarabine (the active ingredient contained in Cytosar) Myelosuppression, anorexia, nausea, vomiting, diarrhea, oral and anal inflammation or ulceration, hepatic dysfunction, fever, rash, thrombophlebitis, bleeding (all sites).
Intrathecal administration of conventional cytarabine: Nausea, vomiting, fever, transient headaches.
Intrathecal administration of liposomal cytarabine: Chemical arachnoiditis (neck rigidity, neck pain, meningism, nausea, vomiting, headache, fever, back pain, and/or CSF pleocytosis), asthenia, pain, confusion, somnolence.
For Healthcare Professionals
Applies to cytarabine: injectable powder for injection, injectable solution
Hematologic side effects including myelosuppression have been the most universal and dose limiting effect of cytarabine (the active ingredient contained in Cytosar) Leukopenia and thrombocytopenia have been reported commonly. Anemia has been reported occasionally.
Myelosuppression has generally been reported to occur four to twelve days after therapy with recovery generally by day twenty eight. It is recommended that the patient's blood counts be monitored throughout therapy and at any clinical sign of thrombocytopenia, fever, or anemia, and before subsequent courses of therapy.
Respiratory side effects including adult respiratory distress syndrome (5% to 32%), sore throat, esophageal ulceration, esophagitis, and shortness of breath have been reported. One case of pulmonary edema has also been reported.
One study has reported 8 of 49 patients treated with high dose cytarabine (the active ingredient contained in Cytosar) developed cerebellar and cerebral toxicity. In another study 4 out of 24 patients developed treated with high dose cytarabine were reported to have developed cerebellar degeneration during treatment. Acute cerebellar toxicity after high dose cytarabine has been associated with CNS accumulation of its metabolite, uracil arabinoside.
Nervous system side effects have been reported in up to 10% of patients and have included neuritis, neural toxicity, cerebellar toxicity, lethargy, confusion, and headache.
Gastrointestinal side effects including oral and anal inflammation or ulceration, anorexia, nausea, vomiting, and diarrhea have been reported frequently. Bowel necrosis, stomatitis, and pancreatitis have also been reported.
Nausea and vomiting have been reported most frequently following rapid intravenous injection.
Hepatic side effects including hepatic dysfunction have been reported frequently. Jaundice has also been reported.
General side effects including fever have been reported frequently. Chest pain, abdominal pain, and dizziness have also been reported.
Dermatologic side effects including rash have been reported frequently. Skin ulceration, freckling, alopecia, pruritus, and urticaria have also been reported. A case of severe Henoch-Schonlein purpura has been reported.
Cardiovascular side effects including thrombophlebitis and bleeding have been reported frequently. Pericarditis has also been reported.
Immunologic side effects including sepsis and pneumonia have been reported.
Local side effects including cellulitis at the injection site have been reported.
Genitourinary side effects including urinary retention and renal dysfunction have been reported.
Ocular side effects including conjunctivitis have been reported.
Hypersensitivity side effects including anaphylaxis and allergic edema have been reported.
Other side effects have included a syndrome of fever, conjunctival suffusion, and maculopapular rash which has been reported primarily in children who received large cumulative doses of cytarabine (the active ingredient contained in Cytosar)
More about Cytosar (cytarabine)
- Other brands: Tarabine PFS
Related treatment guides
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.